Rational design, formulation screening, and performance optimization of liver-targeted lipid nanoparticles for RNA, gene, protein, peptide, and small-molecule delivery.
Liver-targeted lipid nanoparticles (LNPs) remain one of the most strategically important delivery systems for nucleic acid therapeutics and advanced nanomedicine programs. Their hepatic tropism is influenced by lipid composition, particle size, surface chemistry, serum protein adsorption, endosomal release behavior, and liver microenvironment interactions. For drug developers, the central challenge is no longer simply preparing an LNP that reaches the liver, but developing a formulation that delivers the right cargo to the right hepatic cell population with measurable activity, acceptable colloidal behavior, and a development path that can be iteratively optimized.
BOC Sciences provides liver-targeted LNP development services covering formulation design, ionizable lipid selection, ligand-enabled targeting, payload encapsulation, particle characterization, cellular uptake assessment, biodistribution analysis, and formulation optimization. Our service is designed for pharmaceutical researchers, biotechnology teams, and drug development project managers seeking a practical development partner for hepatocyte-directed, liver sinusoidal endothelial cell-oriented, Kupffer cell-associated, or broader hepatic delivery strategies.
Liver-selective LNP development and validationWe build liver-targeted LNP development programs around cargo type, target hepatic cell population, delivery route, particle performance requirements, and downstream evaluation needs. Instead of applying a single template formula, we use a design-make-test-analyze workflow to identify how ionizable lipid structure, helper lipid ratio, cholesterol content, PEG-lipid density, ligand presentation, and process conditions affect liver delivery performance.
We develop LNP systems intended to enhance hepatocyte uptake and intracellular payload release by optimizing particle composition, ApoE interaction potential, pH-responsive lipid behavior, and endosomal escape efficiency.
For projects requiring active hepatocyte targeting, BOC Sciences develops ligand-modified LNP systems with controlled ligand density, spacer architecture, and surface presentation. These systems can be useful when teams need to compare passive liver tropism with receptor-mediated hepatic uptake.
Liver diseases and hepatic biology programs often require delivery beyond hepatocytes. We support formulation exploration for liver sinusoidal endothelial cells, Kupffer cells, hepatic macrophage-associated populations, and hepatic stellate cell-oriented research models.
Liver-targeted LNPs are widely used for RNA and gene delivery because they can protect fragile nucleic acids, enable intracellular transport, and support tunable hepatic biodistribution. BOC Sciences provides formulation services for mRNA LNP delivery, siRNA, RNA, and gene-editing-related payload research.
Payload loading strongly affects formulation potency, dose economy, particle morphology, and release behavior. We optimize encapsulation parameters for nucleic acids, proteins, peptides, and hydrophobic molecules using formulation-specific analytical strategies.
For exploratory programs, we construct formulation matrices that compare lipid composition, PEG-lipid molar ratio, particle size range, ligand density, and processing conditions. This helps teams identify formulation drivers before committing to a narrower candidate set.
Successful liver-targeted LNP development depends on understanding both nanoparticle engineering and hepatic biology. BOC Sciences supports passive, endogenous, and active targeting strategies and can compare them within one integrated formulation program.
From first-pass formulation screening to lead candidate refinement, BOC Sciences helps drug development teams translate hepatic delivery hypotheses into measurable LNP performance.
Our liver-targeted LNP development platform combines formulation engineering, physicochemical characterization, payload analysis, and biological performance evaluation. Each capability can be used independently or combined into a complete development workflow.
| Development Module | Technical Scope and Project Value |
|---|---|
| LNP Formulation Development | Formulation design, lipid ratio screening, buffer selection, N/P ratio optimization, particle size tuning, and lead candidate refinement for hepatic delivery goals. |
| Ionizable Lipid Nanoparticles | Development of pH-responsive LNP systems that support nucleic acid complexation, endosomal escape, and liver-oriented intracellular payload release. |
| LNP Encapsulation | Optimization of cargo loading for mRNA, siRNA, RNA, DNA, proteins, peptides, and selected small molecules using formulation-specific loading strategies. |
| siRNA LNP Delivery | Development of liver-targeted siRNA LNPs for gene knockdown studies, including formulation screening, encapsulation assessment, and functional activity comparison. |
| RNA LNP Delivery | RNA formulation support for hepatic delivery programs requiring payload protection, efficient cellular internalization, and measurable intracellular activity. |
| LNP Gene Delivery | LNP development for plasmid DNA, gene modulation tools, and complex nucleic acid payloads where particle architecture and cargo condensation require careful optimization. |
| LNP Characterization | Particle size, PDI, zeta potential, morphology, encapsulation, lipid composition, and stability-related characterization to support formulation selection. |
| Nanoparticle Cellular and In Vivo Evaluation | Integrated cellular uptake, intracellular delivery, reporter expression, knockdown, tissue distribution, and liver-focused performance evaluation. |
Liver-targeted LNP programs often fail because a formulation that appears strong in one assay performs poorly in another. BOC Sciences helps identify the root causes behind weak activity, inconsistent biodistribution, unstable particles, or unclear cell-type selectivity.
✔ High Liver Uptake but Low Functional Activity
Total liver accumulation does not guarantee cytosolic delivery. We compare uptake, endosomal escape, and functional readouts to determine whether poor activity comes from inefficient release rather than insufficient tissue exposure.
✔ Strong Encapsulation but Unstable Particle Properties
Highly loaded LNPs may show increased size, broad PDI, aggregation, or altered surface charge. We adjust lipid ratios, mixing conditions, and buffer composition to preserve colloidal behavior while maintaining useful payload loading.
✔ Hepatocyte Bias When Non-Parenchymal Delivery Is Needed
Standard LNPs often favor hepatocyte-associated uptake. We explore ligand engineering, size range adjustment, and surface chemistry modulation to shift interaction patterns toward LSECs, Kupffer cells, or other liver-associated cell types.
✔ Ligand Addition Reduces Formulation Quality
Targeting ligands can increase aggregation or reduce encapsulation if surface density and spacer design are not optimized. We screen ligand-lipid ratios and insertion strategies to retain particle quality while improving cell recognition.
✔ Cargo Degradation During Formulation
RNA, protein, and peptide cargos may be sensitive to pH, shear, solvent exposure, or storage conditions. We adapt formulation parameters and analytical handling methods to protect cargo integrity during development.
✔ Unclear Relationship Between Size and Liver Delivery
Small changes in particle size can influence sinusoidal access, serum protein corona formation, and cell-type interaction. We integrate nanoparticle size analysis with biological evaluation to establish formulation-performance relationships.
We review the intended hepatic cell type, cargo format, molecular size, charge profile, stability concerns, and desired biological readout. This information defines the first formulation design space.
Candidate LNPs are prepared by varying ionizable lipid type, helper lipid ratio, cholesterol content, PEG-lipid density, ligand density, N/P ratio, and process parameters.
Formulations are evaluated for particle size, PDI, zeta potential, encapsulation, morphology, stability-related behavior, cellular uptake, intracellular delivery, and functional activity in relevant models.
We rank candidates using a multi-parameter decision matrix and refine selected formulations through additional composition tuning, process optimization, and targeted performance testing.
Challenge: A biotechnology research team developed an mRNA-loaded LNP that showed acceptable encapsulation above 85% and a mean diameter near 90 nm, but reporter expression in hepatocyte-like cells remained weak. Increasing the RNA input improved total signal only marginally and caused broader PDI values.
Diagnosis: BOC Sciences compared six formulation variants with different ionizable lipid/helper lipid ratios and found that the original LNP showed strong cellular association but poor functional delivery. Fluorescent uptake imaging suggested that many particles remained in endosomal compartments. The issue was not uptake, but inefficient endosomal escape.
Solution: We redesigned the formulation panel by adjusting the ionizable lipid molar percentage, replacing the helper lipid component, and reducing PEG-lipid density from the initial screening level. A second-round panel of twelve candidates was prepared and evaluated for particle size, PDI, mRNA encapsulation, serum-containing buffer stability, cellular uptake, and reporter expression. The best-performing candidate maintained a mean size below 100 nm, PDI below 0.15, and strong encapsulation while producing a clear improvement in reporter expression compared with the starting formulation.
Result: The optimized LNP showed approximately 4.8-fold higher reporter expression in the hepatocyte-like model while preserving comparable encapsulation and narrower particle distribution. The client selected two lead formulations for expanded in vitro and in vivo evaluation.
Challenge: A drug discovery group working on a liver-associated gene knockdown program observed potent siRNA activity in mixed liver cell cultures, but follow-up staining suggested excessive uptake by macrophage-like cells. The project goal was to increase hepatocyte-biased activity while reducing non-parenchymal cell-associated signal.
Diagnosis: BOC Sciences profiled the original formulation by size, zeta potential, encapsulation, serum incubation behavior, and cell-type uptake. The formulation had a slightly positive apparent surface profile under test conditions and a broad size distribution extending beyond 140 nm, both of which were associated with increased macrophage-like cell interaction.
Solution: We built a focused optimization matrix with adjusted PEG-lipid ratios, refined microfluidic mixing conditions, and lower surface charge variants. In parallel, we compared non-liganded LNPs with low-density ligand-modified candidates to determine whether receptor-guided uptake could improve hepatocyte preference. The selected formulation showed a tighter 70-90 nm particle population, lower macrophage-like uptake in the cell panel, and preserved siRNA encapsulation above the internal screening threshold.
Result: The lead candidate improved hepatocyte-associated knockdown from 42% to 71% under the same siRNA input condition while reducing macrophage-like cell fluorescence intensity by approximately 45%. This provided the client with a clearer formulation direction for subsequent biodistribution and activity studies.
Hepatic Delivery FocusWe understand that liver targeting is not a single endpoint. Our development strategy distinguishes total liver accumulation, hepatocyte delivery, non-parenchymal cell interaction, and functional intracellular activity.
Integrated LNP PlatformBOC Sciences combines lipid nanoparticles design, encapsulation, characterization, and biological evaluation into a single coordinated workflow.
Cargo-Specific OptimizationWe adapt formulation conditions for mRNA, siRNA, RNA, DNA, proteins, peptides, and small molecules rather than assuming that one hepatic LNP composition works for every payload.
Data-Driven Candidate SelectionCandidate LNPs are ranked using physicochemical and biological criteria, including size, PDI, encapsulation, uptake, intracellular activity, and liver distribution profile.
Optimization Beyond FormulationWhen formulation performance is limited by process variables, we integrate targeted LNP development logic with process parameter refinement to improve reproducibility and performance.
A liver-targeted LNP formulation is defined by more than passive liver accumulation. For drug development teams, the key question is whether the LNP can protect the payload, maintain a suitable particle profile, interact favorably with liver-associated biological pathways, and deliver functional cargo to the intended liver cell population. Important design variables include ionizable lipid structure, helper lipid ratio, cholesterol content, PEG-lipid density, particle size, surface charge, payload chemistry, and buffer environment. BOC Sciences supports liver-targeted LNP development by building formulation matrices, comparing physicochemical properties, and linking analytical data with cellular performance readouts to help identify formulations with stronger liver-relevant delivery potential.
LNPs intended for hepatocyte delivery are usually optimized through iterative adjustment of lipid composition and process parameters rather than a single fixed recipe. Developers often evaluate ionizable lipid pKa, N/P ratio, total lipid-to-payload ratio, PEG-lipid molar percentage, flow rate ratio during microfluidic mixing, and post-formulation buffer exchange conditions. Each parameter can influence particle size, encapsulation efficiency, colloidal stability, serum interaction, uptake, and endosomal release. BOC Sciences can design comparative LNP screening studies that examine multiple formulation variables in parallel, then narrow candidates based on encapsulation, PDI, zeta potential, stability, liver cell uptake, and payload activity. This approach helps customers move from empirical formulation trials toward data-guided liver-targeted LNP optimization.
Liver-targeted LNP systems can be developed for a wide range of payloads, including mRNA, siRNA, antisense oligonucleotides, gene-editing components, plasmid DNA, circular RNA research constructs, peptides, and selected small molecules. Each payload type presents different formulation challenges. mRNA requires protection from degradation and efficient cytosolic release, while siRNA depends strongly on complexation, encapsulation, and intracellular availability. Larger nucleic acids may require special attention to viscosity, shear exposure, and particle heterogeneity. Hydrophobic small molecules may require compatibility testing with the lipid phase and leakage evaluation. BOC Sciences tailors LNP formulation strategies according to payload size, charge, hydrophobicity, stability, and intended liver-cell readout, enabling more rational candidate selection.
Liver-targeted LNP characterization should cover structure, payload association, stability, and biological performance. Key analytical items often include particle size, PDI, zeta potential, morphology, encapsulation efficiency, drug loading content, free payload ratio, nucleic acid integrity, pH-responsive behavior, serum stability, dilution stability, and storage-related changes. For biological evaluation, researchers may examine liver-cell uptake, intracellular trafficking, endosomal escape, target gene knockdown, protein expression, or other payload-specific functional outputs. BOC Sciences integrates formulation preparation with nanoparticle characterization and cell-based assessment, helping customers understand whether an LNP candidate is merely well-formed or genuinely promising for liver-targeted delivery research.
Yes, LNPs can be engineered to explore delivery toward non-hepatocyte liver cells such as Kupffer cells, liver sinusoidal endothelial cells, hepatic stellate cells, and immune-related cell populations. This requires a different design mindset from conventional hepatocyte-focused LNP development. Particle size, lipid composition, surface chemistry, ligand modification, protein corona behavior, and cellular microenvironment can all influence which liver cell types interact with the LNP. For projects seeking non-hepatocyte delivery, BOC Sciences can help compare ligand-free and ligand-modified LNPs, evaluate uptake across relevant liver cell models, and connect formulation differences with cell-selective delivery trends. This supports more informed design of LNP systems for specialized liver biology applications.
